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Abstract
Bilateral injections of the thyrotropin-releasing hormone (TRH) analogue, A/'a-[{(iS')-4-oxo-2-azetidinyl}-carbonyl]-L-histidyI-L- 
prolinamide dihydrate (YM-14673, 0,1 fig and 1 ¿¿g/0.2 ju-1), into the nucleus accumbens, the dorsal and ventrolateral striatum 
produced repetitive jaw movements in a dose-dependent manner. The effects were greatest in the nucleus accumbens and 
smallest in the ventrolateral striatum. Pattern of the movements differed from that produced by injections of a mixture of SKF 
38393 (5 fig) and quinpirole (10 /xg); frequent tongue protrusions were evident in rats treated with the mixture but those were 
not seen in YM-14673-treated rats. TRH (1 fig, 10 jig  and 30 fig/0.2 fi\) did not evoke jaw movements from any of the sites. 
The non-selective dopamine receptor antagonist, ds-(Z)-flupentixoi (10 fig)) significantly reduced the response to administration 
of YM-14673 (1 fig) into the nucleus accumbens or dorsal striatum, while the 5 -hydroxytryptamine (5-HT)2A receptor antagonist, 
2-(2-dimethylaminoethylthio)-3-phenylquinoline hydrochloride (ICl 169,369, 0 .2  f ig \  did not affect the response to YM-14673 (1 
fig). Given intrathecally (0.5 f i g /5 /xl), both YM-14673 and TRH produced wet-dog shakes. Although the mechanisms giving rise 
to the display of jaw movements after intrastriatal injections of YM-14673 remain unknown, stimulation of the dopamine D t/ D 2 
receptors may at least partly contribute to these effects. Anyhow, these mechanisms differ from that underlying the ability of 
YM-14673 and TRH to elicit wet-dog shakes, a mechanism that is known to involve serotonergic processes.
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1. Introduction
Thyrotropin-releasing hormone (TRH) has been 
shown to elicit a variety of biological activities in ani­
mals and man (Prasad, 1987; Yamamoto and Shimizu, 
1987, 1988, 1989; Yamamoto et al., 1990; Matsui et al.,
1994). Many of these effects appear to share a common 
dopaminergic mechanism; for example, (a) potentiation 
of the behavioural effects of l-3,4-dihydroxy phenyl­
alanine (Plotnikoff et al., 1972), (b) induction of ro ta­
tional behaviour in apomorphine-treated mice (Rips
* Corresponding author. Fax 81.3.3219.8136.
and Boschi, 1985), and (c) activation of tyrosine hy­
droxylase (Yokoo et al., 1987). Furtherm ore, it has 
been found that inhibition of dopamine recep­
tors attenuates TR H  effects (Popoli et al., 1991). In ­
deed, dopaminergic terminal areas such as the nucleus 
accumbens receive a dense innervation of TRH-con- 
taining fibres (Johansson et al., 1983) and contain a 
high concentration of TR H  receptors (Taylor and Burt, 
1982). The mechanism underlying T R H  augmentation 
of dopam ine-dependent behaviours is still under dis­
cussion. A part from the conflicting reports concerning 
the ability of TRH  to enhance the release of dopamine 
(Miyamoto et al., 1981; Sharp et al., 1982; Xu et al., 
1990; M éndez et al., 1993), it is also able to inhibit the 
uptake of dopamine (Prasad, 1987, 1991). Although
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these properties may underlie the ability of TRH  to 
alter dopam ine-dependent effects, it cannot underlie 
the wet-dog shakes that are elicited by TRH, since 
5-HT2a receptors appear to be involved in this TR H  
effect (Fone et al., 1989a),
Today, there are several TRH  analogues tha t are 
known to produce T R H  effects. Previously, we have 
shown that the TRH analogue, A^ a-[{(5)-4-oxo-2- 
azetidinyI}-carbonyI]-L-histidyl-L-proIinamide dihydrate 
(YM-14673), elicits dopamine-like behaviours such as 
sniffing and hyperlocomotion (Yamamoto et al., 1990). 
The goal of the present study was to investigate w hether 
YM-14673 is indeed able to elicit dopamine-specific 
behaviour. For that purpose, YM-14673 was injected 
into the nucleus accumbens, the ventrolateral striatum, 
and the dorsal striatum  in order to study its ability to 
elicit dopamine-specific repetitive jaw movements. For 
a long time, it is known that stimulation of dopamine 
D j and D 2 receptors in these brain regions can gener­
ate or modulate such repetitive jaw movements 
(Koshikawa et al., 1987, 1989, 1990a,b; Bordi et al., 
1989; Bordi and Meller, 1989; Kelley et al., 1988, 1989; 
Delfs and Kelley, 1990; Kikuchi de Beltrdn et al., 1992; 
Prinssen et al., 1992; Koene et al., 1993). To study the 
specificity of the response of YM-14673, the ability of 
the dopamine D j/D ^  receptor antagonist cis-(Z )-  
flupentixol (Puech et al., 1981) and the 5-HT2A recep­
tor antagonist ICI 169,369 (Blackburn et al., 1988) to 
attenuate the response of YM-14673 was analysed. 
Finally, YM-14673 was given intrathecally in order to 
investigate w hether this T R H  analogue can elicit wet- 
dog shakes, a T R H  effect that requires an enhanced 
serotonin activity at the level of 5-HT2A receptors 
(Fone et a l ,  1989a,b).
2. Materials and methods
2.1. M easurement o f  jaw  m ovem ents
Surgical procedure
Male Sprague-Dawley rats (260-300 g) were anaes­
thetized with ketam ine H C 1 (1 0  m g /k g  i.p.X supple­
m ented during surgery with halothane (0 .5 - 4 % as ap­
propriate). The surgical and recording procedures were 
as described previously (Koshikawa et al., 1989,1990a,b,
1991). A  small light-emitting diode was fixed to the 
mandible and the animal was placed in a stereotactic 
frame so that the head was kept in constant relation to 
a light-sensitive transducer which detected the vertical 
and horizontal movements of the diode. Bipolar elec­
trodes were placed into the m asseter and digastric 
muscles to record electromyographic (EM G) activity. 
The spinal cord was transected at C l level to confine 
drug-induced jaw movements to the head region. The
Nucleus accumbens Dorsal striatum Ventrolateral striatum
Fig. 1. Injection sites in the nucleus accumbens, the dorsal striatum 
and the ventrolateral striatum. Planes are modified to a series of two 
or three sections for each brain area from the atlas of Paxinos and 
Watson (1986); approximate coordinates indicated are in mm ante­
rior to the interaural line.
jaw movements were recorded on a polygraph for later 
quantification and were counted automatically with a 
spike trigger. Stainless steel guide cannulas (0,5 mm 
o.d., 0.3 mm i.d.) were implanted bilaterally into the 
nucleus accumbens (anterior = 1 0 .6  mm from interau­
ral line; lateral =  1.7 mm from midline; vertical = 3.2 
mm from interaural line), the dorsal striatum  (anterior 
= 9.2 mm; lateral =  3.5 mm; vertical =  6.2 mm) or ven­
trolateral striatum (anterior =  8 .6  mm; lateral =  4 mm; 
vertical =  3.5 mm), according to the  atlas o f Paxinos 
and Watson (1986) (Fig. 1). The nucleus accumbens 
cannulas were angled 2 0 ° from the mid-sagittal plane 
to avoid the ventricular system. A fter surgery, the 
animals were maintained under anaesthesia by contin­
uous infusion of ketamine (10 m g /h  i.v.), Lignocaine 
HC1 (2 %) gel was applied to all incisions and the rectal 
temperature was maintained at 37° C with a thermo­
statically controlled heating pad. M onitored concentra­
tions of expired 0 2 and C 0 2 during the experiment 
were 19-21% and 2.0-2.5% , respectively.
Behavioural observations
The number of jaw openings greater than 1 mm 
(measured from the diode displacem ent) was counted 
in consecutive 5 min periods for 240 min according to 
our paradigms previously described (Koshikawa et at, 
1991; Kikuchi de Beltran et al., 1992). Jaw movements 
and EMG activity were also recorded on a polygraph 
for further analysis of the pattern  of jaw movements 
(see also Koshikawa et al., 1991; Kikuchi de Beltran et 
al., 1992).
YM-14673 (0.1 and 1 ¡¿g) was bilaterally injected 
into each brain structure. For sake of comparison, 
TRH  (1, 10 and 30 fig) was tested in a separate set of 
experiments. The specificity of the responses of YM- 
14673 was studied by co-administering the dopamine 
D j /D 2 receptor antagonist cis-(Z)-flupentixol (10 ju,g) 
or the serotonin 5-HT2A receptor antagonist ICI 
169,369 (0.2 fig) with YM-14673 (1 /xg); intracerebral
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injections were made in 0 .2  /i 1 solution (per side) of a 
mixture of the respective two drugs. The doses of the 
antagonists have previously been found to block effec­
tively apomorphine-induced jaw movements (Koshi- 
kawa et al., 1990b; Kikuchi de Beltran et aL, 1994). 
Since YM-14673 produced responses that could be 
attenuated by c/s-(Z)-flupentixol, it was decided to 
compare the EM G pattern of YM-14673 with that of 
the combined administration of the dopamine D x re­
ceptor agonist SKF 82958 (5 /xg) and the dopamine D 2 
receptor agonist quinpirole (1 0  ¿ig), a treatm ent known 
to elicit dopamine-specific, repetitive jaw movements 
(Koshikawa et al., 1991; Kikuchi de Beltran et al., 
1992). All drugs were dissolved in saline and injected 
bilaterally into the brain sites over 30 s in a volume of 
0.2 jul, and the needle was left in situ for 30 s after 
drug injection.
Histology
A t the end of the experiments, the rats were deeply 
anaesthetized with sodium pentobarbitone, perfused 
transcardially with 1 0 % formaldehyde solution and the 
brains were removed. Injection sites were identified 
from 50 jim  coronal sections stained with cresyl violet. 
The data were analysed only for those animals in which 
injections were correctly placed. Experimental groups 
consisted of six rats and animals were used only once.
2.2. Measurement o f  wet-dog shakes
W et-dog shakes occurring in the individual male 
Sprague-Dawley rats were counted for consecutive 5 
min periods during 90 min after intrathecal injection of 
YM-14673 or TRH. For the intrathecal injections, the 
rats were first anaesthetized with sodium pentobarbi­
tone (50 m g/kg i.p.) to allow a polyethylene catheter 
(8.5 cm length, 0.5 mm o.d.) to be implanted along the 
spinal subarachnoid space, so that the caudal tip of the 
catheter was at the thoraco-lumbar junction of the 
spinal cord (Yaksh and Rudy, 1976). Animals were 
allowed 7 days to recover from surgery; rats showing 
motor dysfunction were eliminated from the study. 
Subsequently, YM-14673 (0.5 fig) and T R H  (0.5 ¡ig) 
were tested. The dose of TRH has previously been 
found to elicit wet-dog shakes (Fone et a l, 1989a). 
Intrathecal injection was made over 30 s in a volume of 
5 ¡i\ followed by 5 til saline for washing.
2.3. Drugs
The drugs used were YM-14673 ( N a-[{(S)-4-oxo-2~ 
azetidinyl}-carbonyl]-L-histidyl-L-prolinamide dihy­
drate, Yamanouchi Pharmaceutical Co.), thyrotropin- 
releasing hormone (TRH, Peptide Institute), SKF 38393 
hydrochloride (l-phenyl-2,3,4,5-tetrahydro-l#-3-benz-
azepine-7,8-diol hydrochloride, Research Biochemicals 
International), quinpirole hydrochloride (Research 
Biochemicals International), cw-iZM lupentixol dihy­
drochloride (Lundbeck) and ICI 169,369 (2-(2-dimeth- 
ylaminoethylthio)-3-phenylquinoline hydrochloride, ICI 
Pharmaceuticals).
2.4. Statistical analysis
All values are expressed as means ±  S.E.M. Time- 
course data were statistically analysed with a two-way 
repeated  analysis of variance (ANOVA) followed by a 
Newman-Keuls multiple comparison test. Total jaw 
movements data were analysed with a one-way ANOVA 
followed by a Newman-Keuls test. Differences were 
considered significant when P  < 0.05.
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Fig, 2. Effects of bilateral injections of saline (0.2 /¿I (o ))  or YM- 
14673 (0.1 jxg ( □ )  or 1 ¿¿g (■ )  in 0.2 fi 1 per side) into the nucleus 
accumbens (A), the dorsal striatum (B) or the ventrolateral striatum 
(C). The data are expressed as mean numbers (six rats in each group) 
of jaw movements occurring in 5-min observation periods. Vertical 
bars indicate S.E.M,
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3. Results A
3.1. E ffects o f  YM-14673 or TRH  injection into the
nucleus accumbens on jaw movements
Bilateral injection of YM-14673 (0.1 and 1 (Mg/02  
jicl per side) dose-dependently elicited repetitive jaw 
movements. The effects of YM-14673 reached maxi­
mum level at 2 0  min after injection and rem ained 
stable until at least 4 h after injection (Fig. 2A). For 
sake of comparison, YM-14673 was also given into the 
ventrolateral or dorsal region of the striatum. YM- 
14673 (0.1 and 1 ¡ig) injected into the dorsal striatum  
elicited repetitive jaw movements, but the effect was 
smaller and slower in onset (the effect reached maxi­
mum at 60 min after injection, Fig, 2B); the smallest 
effect with slowest onset was found, when the com­
pound was given into the ventrolateral striatum: the 
effect reached maximum at 150 m in after injection 
(Fig. 2C). In contrast, T R H  (1 jug and 10 f i g / 0.2 fil) 
failed to evoke any effect (Fig. 3); even a dose of 30 f ig  
TRH remained ineffective, when injected into the nu­
cleus accumbens (data not shown).
3.2, E ffects o f  cis- (Z)-flupentixol on jaw  m ovem ents in ­
duced by YM -14673 injected into the nucleus accumbens 
or dorsal striatum
dK Z )-F lupentixo l (10 fig) injected into the nucleus 
accumbens or the dorsal striatum  significantly reduced
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Fig. 4. Effects of bilateral injections of cw-(Z)-flupentixoI (10 /¿g) 
into the nucleus accumbens (A) or the dorsal striatum (B) on jaw 
movements induced by YM-14673 (1 ^g, ■). For the co-administra­
tion of c/>-(Z )-flupentixol and YM-14673, a m a tu re  of the two drugs 
(in 0.2 fii per side, □ ) was injected intracerebrally. The dala are 
expressed as mean numbers (six rats in each group) of jaw move­
ments occurring in 5-min observation periods. Vertical bars indicate 
S.E.M. * P < 0.05, * * P < 0.01 (Newman-Keuls test).
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the production of jaw movements induced by YM-14673 
(P  < 0.01 for the nucleus accumbens; P  < 0.05 for the 
dorsal striatum, Newman-Keuls test) (Fig. 4).
5,5. Effects o f l C I  169,369 on jaw movem ents induced by 
YM-14673 injected into the nucleus accumbens or dorsal 
striatum
ICI 169,369 into the nucleus accumbens or the dor­
sal striatum failed to affect the jaw movements induced
by YM-14673 (Fig. 5).
3.4. The pattern o f  jaw  m ovem ents including EMG 
changes induced by YM-14673 and the combination of 
SKF 82958 and auinnirole
The pattern of jaw movements occurring after ad­
ministration of YM-14673 (1 fig) into the nucleus ac­
cumbens is illustrated in Fig. 6 , T he upper traces show 
the jaw movements made in the vertical and horizontal 
direction, whereas the lower traces show the EMG 
recordings of the m. digastricus (jaw-opening muscle) 
and m. masseter (jaw-closing muscle), respectively. It 
can be seen that YM-14673 produced large amplitude
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opening and closing movements in the vertical direc­
tion that are followed by small amplitude opening and 
closing movements; the latter were very rapid in com-
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Fig. 7. Wet-dog shakes induced by intrathecal injection of YM-14673 
or TRH. (O) YM-14673 (0.5 ju.g/5 ^  1), (•)  T R H  (0.5 /xg/5 ¿a). Each 
value is the mean of six rats. Vertical bars indicate S.E.M.
parison with the former. Jaw movements in the hori­
zontal direction (lateral jaw movements) were also 
present. The jaw movements were associated with a 
pronounced activity of the digastric muscle and the 
m asseter muscle. The movements were not accompa­
nied by tongue protrusions. This pattern  differed from 
that produced by injections of the dopamine and 
D 2 receptor agonists combination (SKF 82958 5 ¿¿g-f 
quinpirole 1 0  ¡xg / 0 .2  ¿¿,1) into the nucleus accumbens. 
This combination produced a continuous series of 
opening and closing movements of jaw with varying 
amplitude. Digastric and m asseter muscles showed 
continuous activity throughout the period of maximum 
drug effect (Fig. 6 ). Frequent tongue protrusions oc­
curred during the large amplitude jaw openings. This 
pattern  was similar to that described previously 
(Koshikawa et al.3 1991; Kikuchi de Beltran et al., 
1992).
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Fig. 6 . Overall picture of jaw movements (JM) and of electromyographic (EMG) activity of the right anterior digastric muscle (Dig.) and right 
masseter muscle (Mass.) induced by bilateral injections of saline (0.2 /xI), YM-14673 (1 /¿g/0.2 /i\) or combination of SKF 82958 (5 ¿¿g) and 
quinpirole (10 ¡ig) in 0.2 (i\ per side into the nucleus accumbens. Vertical (VERT) and horizontal (HOR) movements of the diode attached to 
the mandibular protuberance are shown along with EM G recordings.
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3.5. Effects o f YM-14673 or TRH  on wet-dog shakes 
induced by intrathecal injection
Intrathecal injection of both YM-14673 (0.5 fig) and 
TRH (0.5 jig) elicited wet-dog shakes: the effect of 
YM-14673 was greater and longer lasting than that of 
TRH (Fig. 7).
4. Discussion
YM-14673 injected into the nucleus accumbens, 
dorsal striatum or ventrolateral striatum elicited repet­
itive jaw movements in a dose-related manner. The 
response to accumbens injections was the greatest, 
whereas that to injections into the ventrolateral stria­
tum was the smallest. These findings exclude the possi­
bility that YM-14673 diffused from the nucleus accum­
bens to the dorsal striatum, or vice versa. Thus, it can 
be concluded that both the nucleus accumbens and the 
dorsal striatum play a role in jaw movements elicited 
by YM-14673, Since the response of YM-14673 was
•»
attenuated by the dopamine D x/ D 2 receptor antago­
nist c£y-(Z)-flupentixol, but not by the 5-HT2A antago­
nist ICI 169,369, it is suggested that YM-14673 directly
or indirectly enhanced the dopamine activity at the 
level of dopamine D x/ D 2 receptors, but not the sero­
tonin activity at the level of 5-HT2A receptors. Indeed, 
stimulation of dopamine D L and D 2 receptors in the 
nucleus accumbens also elicits repetitive jaw move­
ments. However, there are at least three findings indi­
cating that YM-14673 must have additional effects,
i
First, the pattern of jaw movements induced by YM- 
14673 is not identical to that elicited by stimulation of 
dopamine D t and D 2 receptors (Fig. 6 )* Although the 
differences in number and amplitude of jaw move­
ments may have resulted from differences in the de­
gree in which the dopaminergic postsynaptic activity is 
altered by uptake inhibition (YM-14673) and direct 
receptor stimulation (SKF 82958 + quinpirole), the ab­
sence (YM-14673) or presence (SKF 82958 +  
quinpirole) of tongue protrusions cannot be ascribed to 
such differences. Secondly, YM-14673 was nearly inef­
fective after injections into the ventrolateral striatum, 
but reasonably effective after injections into the dorsal 
striatum (Fig. 3). In contrast, stimulation of dopamine 
D x and D 2 receptors is most effective after injections 
into the ventrolateral striatum, but ineffective after 
injections into the dorsal striatum 1 (Koshikawa et aL,
1989). Finally, the effects of YM-14673 could be 
blocked only partially by a dose of the dopamine D l/ D 2 
receptor antagonist cis-(Z)-flupentixol that is highly 
effective in blocking the effects of dopamine receptor 
agonists upon jaw movements (Koshikawa et aL, 1990b). 
These data together strongly suggest that YM-14673 
has additional effects, apart from those upon the
dopamine transmission. The finding that YM-14673 
like TRH  elicits wet-dog shakes underscores this con­
clusion, since TRH-induced wet-dog shakes appear to 
need an enhanced serotonin activity (Fone et aL, 
1989a,b). However, the present study excludes the pos­
sibility that changes in the serotonin transmission con­
tribute to the effect of YM-14673 upon jaw move­
ments, since the 5-HT2A receptor antagonist remained 
devoid of any effect.
The finding that TR H  itself was unable to elicit jaw 
movements is difficult to understand. Since TRH is 
more susceptible to peptidases than YM-14673 (Grif­
fiths et aL, 1980; Nakamura et aL, 1991), it can be 
speculated that TRH was too rapidly metabolized in 
the brain structures under study in order to stimulate 
sufficiently the receptors involved.
Taking the above-mentioned findings and considera­
tions together, it appears that the TRH analogue YM- 
14673 can induce its behavioural effects by at least two 
different mechanisms. First, it can stimulate TRH re­
ceptors and, consequently, produces wet-dog shakes 
involving alterations in the serotonin transmission. Sec- 
ond, it can directly a n d /o r  indirectly enhance the 
dopamine activity at the level of dopamine D j /D 2 
receptors in certain brain structures. Although the 
latter mechanism may at least partly contribute to the 
ability of YM-14673 to elicit jaw movements after in­
jections into the nucleus accumbens, the dorsal stria­
tum  and, possibly, the ventrolateral striatum, it is evi­
dent that additional mechanisms must play a role in 
the display of jaw movements.
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